AKTS Insider Trading Activity and SEC Form 4 Filings
AKTS insider trading summary
Over the past 12 months, insiders at Aktis Oncology, Inc. (AKTS) reported 22 open-market purchases worth $349.6M by 17 insiders and 11 sales worth $3.2M by 3 insiders on SEC Form 4. Net insider buying was $346.4M.
Latest AKTS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 23, 2026 | Akos Czibere | Chief Medical Officer | Sell | $103K (5,099 @ $20.19) |
| Sep 23, 2026 | Akos Czibere | Chief Medical Officer | Sell | $156K (7,401 @ $21.03) |
| Jul 20, 2026 | Ken Herrmann | Insider | Sell | $33K (1,350 @ $24.56) |
| Jul 20, 2026 | Ken Herrmann | Insider | Sell | $86K (3,506 @ $24.56) |
| Jul 17, 2026 | Ken Herrmann | Insider | Sell | $77K (3,065 @ $25.21) |
| Jul 8, 2026 | Shulamit Ron-Bigger | Chief Operating Officer | Sell | $838K (30,000 @ $27.94) |
| Jul 8, 2026 | Akos Czibere | Chief Medical Officer | Sell | $862K (30,829 @ $27.95) |
| Jul 8, 2026 | Akos Czibere | Chief Medical Officer | Sell | $401K (14,800 @ $27.13) |
| Jul 8, 2026 | Shulamit Ron-Bigger | Chief Operating Officer | Sell | $429K (15,800 @ $27.13) |
| Jul 8, 2026 | Akos Czibere | Chief Medical Officer | Sell | $125K (4,371 @ $28.71) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.